How one cell transplant platform is poised to tackle complex diseases
Lineage Cell Therapeutics CEO Brian Culley discusses the company's cell therapy technology with ScienceBoard.net. The technology involves the transplantation of differentiated stem cells as part of an off-the-shelf allogeneic cell therapy. Read More
Sirnaomics, Walvax team up on anti-influenza siRNA
Sirnaomics Biopharmaceuticals has entered into a partnership with Walvax Biotechnology for the co-development of STP702, its anti-influenza short interfering RNA therapeutic candidate. Read More
Thermo Fisher to sell Progen primary antibodies
Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific. Read More
Brooklyn licenses mRNA cell reprogramming platform
Brooklyn ImmunoTherapeutics has acquired an exclusive license for messenger RNA (mRNA) gene editing and cell therapies technology from Factor Bioscience and Novellus Therapeutics as an exercise of a previously announced option. Read More
Forge secures $120M to increase AAV manufacturing capacity
Contract development and manufacturing organization Forge Biologics has closed $120 million in financing to accelerate the expansion of its adeno-associated virus (AAV) manufacturing capabilities Read More
Albumedix, Cobra partner on viral vector manufacturing
Albumedix and Cobra Biologics, the gene therapy division of Cognate BioServices, will collaborate on viral vector manufacturing. Read More
Boundless Bio nabs $105M for ecDNA-directed cancer therapy
Boundless Bio has secured $105 million in financing to advance multiple extrachromosomal DNA (ecDNA)-directed therapeutic programs into the clinic along with an accompanying ecDNA harboring oncogene (ECHO) companion diagnostic. Read More
Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery for drug development. Read More
Avantor increases manufacturing of single-use technology
Avantor plans to increase its manufacturing capability of single-use technologies for biologics and vaccines. Read More
LogicBio signs collaborations with Daiichi Sankyo and Canbridge
LogicBio has signed separate collaboration and option agreements with Daiichi Sankyo and Canbridge Pharmaceuticals in China for the development of therapies based on LogicBio's GeneRide gene insertion platform. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter